FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							,,, oo(ii)	01 1110	iiiv courie		inpuny Act	01 10-10								
1. Name and Address of Reporting Person* Fong Bryant						2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]									Relationship of Reporting Person(s) to Issuer (Check all applicable)					
												-		2	V Director	or		10% O	wner	
(Last) (First) (Middle) C/O ADMA BIOLOGICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/19/2014										Officer below)	(give title		Other (below)	specify	
·																				
465 STATE ROUTE 17					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line	,	::		ti D		
RAMSE	y N	NJ												1	_	,		orting Perso		
															Perso		re tnar	n One Repo	orting	
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	ı-Deriv	ative	Sec	curitie	s Ac	quired	, Dis	posed o	of, or B	enef	iciall	y Owned	ı				
Date				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.						es Fo ially (D) Following (I)		vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	Amount (A) or (D)		Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
		Т	able II - I								osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	ate, Transac				6. Date E Expiratio (Month/D	n Date	•	e and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa		Expiration Date	Title	or Nu of	nount mber ares						
Options to purchase	\$8.5 ⁽¹⁾	06/19/2014			A		9,000		(2)		06/18/2024	Commo	9,	000	\$0	9,000		D		

Explanation of Responses:

1. The exercise price reflects the per share fair market value of the Company's common stock, as determined by the closing price of the Company's common stock on the OTC Bulletin Board on February 21, 2014, the date that the option grant was approved by the Company's board of directors, subject to stockholder approval of the 2014 Omnibus Incentive Compensation Plan (the "Plan") under which the option was granted. The Company's stockholders approved the Plan on June 19, 2014.

2. These options will vest monthly over a period of 24 months and terminate 12 months following separation.

/s/ Bryant Fong 06/19/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.